Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rangering i aksjer
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aksjekurs
$4.87
Markedsverdi
$4.36B
Endring (1 dag)
-5.47%
Endring (1 år)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategori
Healthcare
Antall utestående aksjer for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Antall utestående aksjer per October 2026: 0
Ifølge Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av October 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336) fra 2006 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2025 | 617.38M | -0.11% |
| 2024 | 618.05M | 0.70% |
| 2023 | 613.78M | -0.40% |
| 2022 | 616.22M | 2.37% |
| 2021 | 601.95M | 2.42% |
| 2020 | 587.73M | 10.22% |
| 2019 | 533.24M | 4.51% |
| 2018 | 510.22M | 0.00% |
| 2017 | 510.22M | 0.86% |
| 2016 | 505.85M | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 508.39M | -1.58% |
| 2011 | 516.57M | 8.92% |
| 2010 | 474.28M | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
